NDA Partners LLC: A Development Partner to Biopharmaceutical Investors and Companies

David Savello, PhD

Practice Area Focus

  • Product Development
  • Process Chemistry
  • Drug Metabolism
  • Toxiology
  • Bioanalytics
  • Clinical Pharmacology


Dr. Savello is a founder and Partner in NDA Partners. He formerly served as Senior Vice President for Development Operations at XenoPort, Inc. Prior to XenoPort, Dr. Savello was Executive Vice President and Chief Scientific Officer for Cardinal Health, and Senior Vice President for Drug Development at Guilford Pharmaceuticals. Dr. Savello also worked at Glaxo and Glaxo Wellcome for more than 11 years as both Vice President Drug Development and Vice President Regulatory Affairs and Compliance. While at Glaxo and Glaxo Wellcome, he was responsible for the development and regulatory submission and approval of a number of products including Serevent®, Flovent®, Flonase®, Imitrex®, Epivirv, Zofran®, and Zantac® Rx to OTC switch. He also had R&D management and executive management positions at Boehringer Ingelheim and 3M Riker Laboratories.